Painreform Ltd (NASDAQ:PRFX) — Market Cap & Net Worth
Market Cap & Net Worth: Painreform Ltd (PRFX)
Painreform Ltd (NASDAQ:PRFX) has a market capitalization of $1.81 Million ($1.81 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30204 globally and #6144 in its home market, demonstrating a -7.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Painreform Ltd's stock price $0.90 by its total outstanding shares 2013141 (2.01 Million). Also see Painreform Ltd assets under control for a full breakdown of the balance sheet.
Painreform Ltd Market Cap History: 2020 to 2026
Painreform Ltd's market capitalization history from 2020 to 2026. Data shows change from $2.16 Billion to $1.81 Million (-71.08% CAGR). Also see PRFX cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Painreform Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #884 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #2815 of 3165 |
Weight: Painreform Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Painreform Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Painreform Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Painreform Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2318.58x
Painreform Ltd's market cap is 2318.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $199.40 Million | $86.00K | -$8.79 Million | 2318.58x | N/A |
Competitor Companies of PRFX by Market Capitalization
Companies near Painreform Ltd in the global market cap rankings as of September 17, 2026. Review Painreform Ltd (PRFX) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Painreform Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Painreform Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Painreform Ltd's market cap moved from $2.16 Billion to $ 1.81 Million, with a yearly change of -71.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.81 Million | +40.23% |
| 2025 | $1.29 Million | -80.87% |
| 2024 | $6.75 Million | -94.92% |
| 2023 | $132.87 Million | -33.37% |
| 2022 | $199.40 Million | -68.97% |
| 2021 | $642.59 Million | -70.25% |
| 2020 | $2.16 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Painreform Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.81 Million USD |
| MoneyControl | $1.81 Million USD |
| MarketWatch | $1.81 Million USD |
| marketcap.company | $1.81 Million USD |
| Reuters | $1.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more